DOPAMINE ACTIVITY AND OMAPATRILAT, “IN VITRO”, AND IN AN EXPERIMENTAL MODEL OF TYPE II DIABETES MELLITUS (DM-II) WITH KIDNEY DAMAGE | Publicación